Clinical Trial Update: A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM) [Phase 2]

View source ↗

Summary

The ADAPTeM Phase 2 trial of pembrolizumab for metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Advanced Melanoma | Phase 2 | Status: WITHDRAWN